Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment

Heart

Volumn 89, Issue 5, 2003, Pages 535-537

  Brown, David L ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE; TIROFIBAN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; DEATH; DRUG EFFECT; DRUG SAFETY; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0037407217     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.5.535     Document Type: Article

References (26)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cordiovascular medicine. N Engl J Med 1995;332:1553-9.
2. Narins CR, Topol EJ. Attention shifts to the white clot. Lancet 1997;350(suppl 2):2.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
4. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
6. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasly-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIo blockade. Lancet 1998;352:87-92.
7. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
8. The ESPRIT Investigators. Novel dosing regimen in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
9. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
10. The PRISM-PLUS Study Investigators. Inhibition of the platelet IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
11. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
12. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
13. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa Integrin blockade. Circulation 1998;98:2629-35.
14. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13.
15. Kalra S, Bell MR, Rihal CS. Alveolar hemorrhage as a complication of treatment with abciximab. Chest 2001;120:126-31.
16. Ali A, Patil S, Grady KJ, et al. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors. Cathet Cardiovasc Intervent 2000;49:181-4.
17. Vahdat B, Canavy I, Fourcade L, et al. Fatal cerebror hemorrhage and severe thrombocytopenia during abciximab treatment. Cathet Cardiovasc Intervent 2000;49:177-80.
18. Blanc S, Leuenberger P, Berger JP, et al. Judgments of trained observers on adverse drug reactions. Clin Pharmacol Ther 1979;25:493-8.
19. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
20. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa Integrin in Ischemic heart disease. Circulation 1998;98:2829-35.
21. Akkerhuis KM, Deckers JW, Lincoff AM, et al. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA 2001;286:78-82.
22. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286:708-13.
23. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised trials. Lancet 2002;359:189-98.
24. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
25. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-15.
26. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74-80.